Pfizer exits neuroscience

Nature Reviews Drug Discovery 17, 86 (2018). doi:10.1038/nrd.2018.16 Author: Asher Mullard Pfizer is pulling out of neuroscience drug discovery and early development, and cutting 300 positions in its neuroscience division.Prior to the announcement, the company had eight neuroscience products in phase I and phase II trials. These consisted of four clinical programmes in Alzheimer disease,
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research